What is HC Wainwright’s Forecast for PLRX FY2029 Earnings?

Pliant Therapeutics, Inc. (NASDAQ:PLRX) – Investment analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of Pliant Therapeutics in a research report issued on Monday, February 10th. HC Wainwright analyst E. Arce forecasts that the company will post earnings per share of $1.75 for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Pliant Therapeutics’ current full-year earnings is ($3.65) per share.

A number of other equities analysts have also weighed in on the company. Oppenheimer reaffirmed a “market perform” rating on shares of Pliant Therapeutics in a research report on Monday. JPMorgan Chase & Co. downgraded shares of Pliant Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday. Canaccord Genuity Group reiterated a “hold” rating and set a $4.00 price objective (down from $43.00) on shares of Pliant Therapeutics in a report on Monday. Wells Fargo & Company lowered shares of Pliant Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $41.00 to $4.00 in a report on Monday. Finally, Citigroup downgraded Pliant Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the company from $40.00 to $4.00 in a research note on Monday. Seven research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pliant Therapeutics currently has an average rating of “Hold” and an average price target of $17.75.

Pliant Therapeutics Stock Down 15.0 %

Shares of NASDAQ:PLRX opened at $2.61 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.26 and a current ratio of 10.26. Pliant Therapeutics has a 52-week low of $2.60 and a 52-week high of $18.00. The business’s 50 day simple moving average is $12.18 and its two-hundred day simple moving average is $12.79. The firm has a market cap of $158.82 million, a P/E ratio of -0.78 and a beta of 1.03.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PLRX. R Squared Ltd bought a new position in shares of Pliant Therapeutics during the 4th quarter worth $33,000. KLP Kapitalforvaltning AS purchased a new stake in Pliant Therapeutics during the fourth quarter valued at about $108,000. Atria Investments Inc bought a new position in Pliant Therapeutics during the third quarter worth about $112,000. China Universal Asset Management Co. Ltd. boosted its position in Pliant Therapeutics by 65.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,694 shares of the company’s stock worth $131,000 after purchasing an additional 4,607 shares during the period. Finally, Intech Investment Management LLC purchased a new position in shares of Pliant Therapeutics in the third quarter worth about $145,000. 97.30% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Pliant Therapeutics

In related news, General Counsel Mike Ouimette sold 10,230 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $10.99, for a total value of $112,427.70. Following the transaction, the general counsel now directly owns 70,544 shares of the company’s stock, valued at approximately $775,278.56. The trade was a 12.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bernard Coulie sold 52,419 shares of the firm’s stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $11.20, for a total transaction of $587,092.80. Following the sale, the chief executive officer now owns 430,517 shares of the company’s stock, valued at $4,821,790.40. This trade represents a 10.85 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 91,855 shares of company stock worth $1,026,628. Insiders own 6.40% of the company’s stock.

About Pliant Therapeutics

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.